The Catalyst

Most Recent Posts

08.14.14 | By Preet Bilinski

This week, CNBC Nightly Business Report’s series “Aging in America” addressed the impact the rapidly aging U.S. population has on the health care system. Bill Chin, PhRMA’s Executive Vice President of Science and Regulatory Affairs, discusses the issue.

drug safety
08.14.14 | By Preet Bilinski

Pharmaceutics is that area of biomedical and pharmaceutical sciences that deals with drug delivery systems, in particular the design and evaluation of contemporary pharmaceutical dosage forms so that they are safe, effective, and reliable.

08.14.14 | By Jennifer Wall

“Despite rigorous and extensive testing for safety and efficacy, a single piece of widely circulated false information can have lasting impact on the public’s perception on vaccine safety.” This month is National Immunization Awareness Month, and as children go back to school, this comment by Conversations contributor Roberta DeBiasi of the Child

phrma second annual national health survey
08.13.14 | By Kaelan Hollon

This week we released From Hope to Cures: PhRMA’s Second Annual National Health Survey revealing new data on how Americans view their own health as well as that of the Nation. The survey also reveals three new trends that appear to be evolving under the shifting health care landscape.

08.08.14 | By Kaelan Hollon

How we can further improve patients’ lives? This is a question the biopharmaceutical industry is constantly asking. This week on the Catalyst we noted that one way to achieve this is by supporting ways to ensure patients receive, and benefit from treatments.

08.05.14 | By Jennifer Wall

A national dialogue is needed around the value of new medicines and cures and the role they play in improving patient health and helping to manage long-term spending in the U.S. health care system. Unfortunately, the debate around hepatitis C has, for the most part, been twisted to the point that modern-day cures are seen as a nuisance rather than a monumental step forward in the battle against disease. (This post was updated on August 5, 2014.)

improved quality of life for patients with arthritis
08.04.14 | By Robert Zirkelbach

For many patients, hope for a brighter future is directly tied to the potential of medicines in the pipeline to treat their disease or condition.

08.04.14 | By Preet Bilinski

Today, more than 52 million Americans are affected by arthritis and related musculoskeletal diseases, consisting of more than 100 different conditions, according to the U.S. Centers for Disease Control and Prevention (CDC). The CDC projects prevalence of musculoskeletal diseases could increase to 67 million by 2030 if current trends continue.

08.04.14 | By Allyson Funk

Medicare Part D continues to be a success for beneficiaries.

08.01.14 | By Kaelan Hollon

This week was packed with lively and informative discussions surrounding the incredibly important issue of treatment costs and the need to incorporate value into the cost narrative.

07.31.14 | By Jay Taylor

Following up on our May post, the next chapter in the rebuilding of the U.S. – India relationship has begun, as U.S. Secretary of State John Kerry and Secretary of Commerce Penny Pritzker are in India to meet with their counterparts in the new Indian government. Secretary Kerry will partake in the fifth U.S.-India Strategic Dialogue and also meet with Prime Minister Modi, the first meetings to occur between high-ranking officials from the U.S.

07.31.14 | By Jennifer Wall

Earlier this week, PhRMA participated in the Wall Street Journal’s first tweet chat hosted by Ed Silverman, who spearheads the publication’s blog, Pharmalot.

07.29.14 | By Jennifer Wall

For the millions of patients battling hepatitis C, World Hepatitis Day will hopefully be a day that is only read about in history books.

Now, more than ever before, there is great hope on the horizon as new and forthcoming medicines can provide nearly all patients fighting this disease with a cure. 

07.25.14 | By Kaelan Hollon

Biopharmaceutical research and development (R&D) continues to thrive. This week, we examined some of the ways that medicines in development have opened new doors for patients and what we can do to maintain a bright and promising future.

07.25.14 | By Jennifer Wall

The current debate regarding the cost of new and forthcoming hepatitis C treatments has brought to light a long-standing discussion about the cost and value of innovative new medicines.

Pages